OPKO Health, Inc.
NASDAQ:OPKBiotechnology
+$0.01 today
- Market cap
- $1.25B
- Beta
- 1.49
- P/E (TTM)
- -5.1
- EPS (TTM)
- -$0.28
Volume 3.06M
Average 2.59M
OPK EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
OPKO Health, Inc.NASDAQ: OPK
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$27.82M, compared with -$34.43M a year earlier. Trailing-twelve-month EBITDA was -$34.69M.
Context
- EBITDA amounted to 6.8% of revenue in FY2025, down 12.2 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 4 analysts of -$35.87M (+13.2%) for the fiscal year ending Dec 2026, a step up from the -130.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$27.82M-110.2% QoQ
- Last fiscal yearDec 2025
- -$41.3M-130.5% YoY
- LTMMar 2026
- -$34.69M-123.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +19.2% | +70.4% | +51.2 pp |
| 1 year | -130.5% | +13.2% | +143.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (41.3M) USD
- Year-over-year change
- -130.5%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (41.3M) | -130.5% |
| FY2024 | 2024-12-31 | 135.28M | +306.5% |
| FY2023 | 2023-12-31 | (65.52M) | +75.8% |
| FY2022 | 2022-12-31 | (270.81M) | -424.0% |
| FY2021 | 2021-12-31 | 83.57M | — |
EBITDA vs competitors
How OPK compares with its peers on the latest reported figures
- OPK's LTM Mar 2026 EBITDA of -$34.69M is the 6th highest of the 11 companies compared; the peer median is -$36.26M.
- Its year-over-year change of -123.1% is the 9th highest of 11, against a peer median of -14.2%.
- EBITDA amounts to 6.0% of revenue for OPK, versus a peer median of 15.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
BLLNBillionToOne, Inc. | LTM Jun 2026 | $50.25M | +362.6% | — | 12.6% |
| LTM Jun 2026 | $12.89M | +145.3% | — | 1.7% | |
| LTM Mar 2026 | -$725.67K | -101.8% | — | 0.2% | |
| LTM Mar 2026 | -$12.91M | -11.7% | — | 18.9% | |
| FY2025 | -$14.01M | +36.4% | — | 13.0% | |
| LTM Mar 2026 | -$34.69M | -123.1% | — | 6.0% | |
| LTM Mar 2026 | -$58.51M | -133.4% | — | 18.3% | |
| LTM Mar 2026 | -$85.53M | -16.7% | — | 132.6% | |
| LTM Jun 2026 | -$178.71M | +15.6% | — | 6.6% | |
| LTM Mar 2026 | -$334.2M | -423.0% | — | 40.3% | |
| LTM Sep 2026 | -$441.45M | -24.7% | — | 34.5% | |
| Peer median (excluding OPK) | -$36.26M | -14.2% | — | 15.6% | |
Competitors are the stored peer set for OPK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.77B | 1B | 863.5M | 713.14M | 606.88M |
| Cost of Revenue | 1.19B | 715.98M | 545.37M | 402.11M | 478.83M |
| Gross Profit | 581.52M | 288.22M | 318.13M | 311.03M | 128.05M |
| Gross Margin | 32.8% | 28.7% | 36.8% | 43.6% | 21.1% |
| Research & Development | 76.85M | 73.89M | 89.59M | 105.21M | 124.03M |
| Selling, General & Admin | 468.86M | 372.67M | 300.56M | 304.22M | 223M |
| Operating Expenses | 562.77M | 514.47M | 475.15M | 463.1M | 347.04M |
| Depreciation & Amortization | 78.72M | 108.66M | 105.3M | 98.18M | 91.63M |
| EBITDA | 83.57M | (270.81M) | (65.52M) | 135.28M | (41.3M) |
| EBITDA Margin | 4.7% | -27.0% | -7.6% | 19.0% | -6.8% |
| Operating Income | 18.75M | (226.25M) | (157.02M) | (152.07M) | (218.99M) |
| Operating Margin | 1.1% | -22.5% | -18.2% | -21.3% | -36.1% |
| Interest Income | 28K | 1.98M | 3.98M | 8.43M | 14.81M |
| Interest Expense | 18.88M | 12.06M | 13.51M | 47.47M | 108.46M |
| Other Income / Expenses | (33.4M) | (165.65M) | (27.41M) | 141.7M | (22.41M) |
| Income Before Tax | (14.65M) | (391.9M) | (184.43M) | (10.36M) | (241.39M) |
| Pre-Tax Margin | -0.8% | -39.0% | -21.4% | -1.5% | -39.8% |
| Income Tax Expense | 15.49M | (63.5M) | 4.44M | 42.84M | (15.71M) |
| Net Income | (30.14M) | (328.41M) | (188.86M) | (53.22M) | (225.68M) |
| Net Margin | -1.7% | -32.7% | -21.9% | -7.5% | -37.2% |
| EPS (Basic) | (0.05) | (0.46) | (0.25) | (0.08) | (0.30) |
| EPS (Diluted) | (0.05) | (0.46) | (0.25) | (0.08) | (0.30) |
| Weighted Avg Shares | 648.08M | 719.06M | 751.77M | 694.02M | 751.13M |
| Weighted Avg Shares (Diluted) | 648.08M | 719.06M | 751.77M | 694.02M | 751.13M |
OPKO Health, Inc.
NASDAQ:OPK
Intrinsic Alpha fair value
Locked
Current Price
$1.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.